It’s not just our CLL that determines how well we do. It is also what other illness we have. At EHA 2019, Dr. Danilov discusses his findings related to our co-morbidities: cllsociety.org/2019/11/eha-...
The phase III Alliance A041202 collaborative multi-centered trial demonstrated once and for all the superiority of ibrutinib versus Bendamustine/Rituximab (BR) when used frontline in older CLL patients. Dr. Brander from Duke fills in more details at iwCLL 2019 in Scotland: cllsociety.org/2020/01/iwcl...
I update my CLL journey with good news on my scans and blood test, my plans and the loss of a famous friend: cllsociety.org/2020/01/all-....
Stay strong. We are all in this together.
Hope to see some of you at City of Hope tomorrow morning at the CLL Society's educational forum. You can just show up and register there.
Stay strong. We are all in this together
Brian
CMO and EVP, CLLSociety.org